Wellness Focus Cayman Islands
SEE OTHER BRANDS

Get your health and wellness news from the Cayman Islands

Wellness Focus Cayman Islands: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Focus Cayman Islands.

Press releases published on June 25, 2025

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B …

Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia

Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing …

Eyenovia Announces Co-Branded Validator with Kinetiq 

Eyenovia Announces Co-Branded Validator with Kinetiq 

LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of …

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions

RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results …

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a …

Wearable Devices Advances AI Health Monitoring Platform as U.S. HHS Embraces Wearable Tech

Wearable Devices Advances AI Health Monitoring Platform as U.S. HHS Embraces Wearable Tech

Yokneam Illit, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, …

OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress

OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress

MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD) announced today that Aaron Green, President and CEO, issued the following letter to …

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that its …

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combat Group A Streptococcus (GAS) New vaccine program is added to Evaxion’s pipeline under the name EVX-B4 Urgent need for preventive …

Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors

Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of …

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 ( …

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort …

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Combination cohort initiated following successful review of monotherapy cohort Over 100 participants dosed to-date in monotherapy cohort Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer Data update on schedule for later this …

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three …

Bryn Pharma Announces First Participant Dosed in PK/PD Trial with Upgraded Nasal Spray Device, Including First-of-Its-Kind, Two-Doses-in-One Nasal Spray Profile

Bryn Pharma Announces First Participant Dosed in PK/PD Trial with Upgraded Nasal Spray Device, Including First-of-Its-Kind, Two-Doses-in-One Nasal Spray Profile

New clinical trial data with Bryn Pharma’s second-generation epinephrine nasal spray expected in Q3 2025 The trial employs an upgraded two-spray nasal spray device providing additional reliability and user experience enhancements Trial includes evaluation …

ORYZON to Host Virtual KOL Event on July 9, 2025

ORYZON to Host Virtual KOL Event on July 9, 2025

MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on …

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger …

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference

REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide …

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. ( …

Basecamp Research Announces Malawi Biodiscovery Partnership in Series of New Collaborations Across Three Continents at UK Government Nature Action Event

Basecamp Research Announces Malawi Biodiscovery Partnership in Series of New Collaborations Across Three Continents at UK Government Nature Action Event

Partnerships with Malawi, Hungary, and other new partners will rapidly expand BaseData, the largest biological protein database designed specifically for training generative AI foundation models to improve drug discovery and planetary health. …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service